Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains

Yuchen Wu; Xuemei Yang; Congcong Liu; Yanyan Zhang; Yan Chu Cheung; Edward Wai Chi Chan; Sheng Chen; Rong Zhang

doi:10.1128/spectrum.02655-21

Author(s)

Yuchen Wu
Congcong Liu
Yanyan Zhang
Edward Wai Chi Chan
Rong Zhang

Related Research Unit(s)

Detail(s)

Original language	English
Journal / Publication	Microbiology Spectrum
Volume	10
Issue number	2
Publication status	Published - Mar 2022

Link(s)

DOI	DOI https://doi.org/10.1128/spectrum.02655-21 Final Published version
	Check@CityULib
Attachment(s)	Documents 101169961.pdf Final Published version, 4.83 MB, PDF Publisher's Copyright Statement This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/
Link to Scopus	https://www.scopus.com/record/display.uri?eid=2-s2.0-85129343585&origin=recordpage
Permanent Link	https://scholars.cityu.edu.hk/en/publications/publication(eac277e4-dca0-40e6-92b1-f8eda20385b0).html

Abstract

A novel Klebsiella pneumoniae carbapenemase (KPC) variant, KPC-93, was identified in two Klebsiella pneumoniae clinical isolates from a patient from China treated with ceftazidime-avibactam. KPC-93 possessed a five-amino-acids insertion (Pro-Asn-Asn-Arg-Ala) between Ambler positions 267 and 268 in KPC-2. Cloning and expression of the bla_KPC-93gene in Escherichia coli, followed by determination of minimum inhibitory concentration (MIC) values and kinetic parameters, showed that KPC-93 exhibited increased resistance to ceftazidime-avibactam, but a drastic decrease in carbapenemase activity. Our data highlight that a KPC variant conferring resistance to ceftazidime-avibactam could be easily induced by ceftazidime-avibactam treatment and that actions are required to control dissemination of these determinants.